Koo,

"new findings that suggest its Apabetalone treatment prior to COVID-19 exposure could significantly reduces viral infecion"

Haven't read the PNAS article yet, but the news report suggests that treatment would or could be prior to infection, therfore prophylactic.  It might also work as a therapeutic after infection but it would likely have to be very soon because viral replication and spread happen quickly.

I have long believed that prophylactic apabetalone use might become standard because there is little point in allowing the increasing inflammatory milieu that is associated with ageing to become a full-blown disease state (diabetes, MACE, etc.) before applying the brakes.

Jupe